Teleperformance SE shares dropped sharply after JPMorgan reinstated coverage of the company with an Underweight recommendation and a EUR 44 price target, a move that sent the stock down 5.9% to trade at €51.96 during the session.
JPMorgan’s valuation work lies well below prevailing market expectations. The bank’s forecasts are approximately 2% lower than Bloomberg consensus for operating EBITA and about 12% below consensus for free cash flow. Its discounted cash-flow model anticipates a low-single-digit decline in free cash flow through 2026–30, followed by an accelerating 5% annual decline over 2031–35, and assumes zero terminal growth - a profile that frames the business as structurally challenged under the bank’s assumptions.
The downgrade compounded an already fragile setup. A recent guidance cut from competitor Concentrix - which trimmed its full-year 2026 revenue and profit outlook while citing rising client financial pressure - was read by investors as a broader signal that AI-driven automation could be displacing the human-led contact-centre work that underpins Teleperformance’s revenues. Against that backdrop, Teleperformance’s own first-quarter 2026 results were soft: group revenue fell 2.2% on a like-for-like basis, missing the company’s 0–2% full-year growth target. The firm’s technical indicators are also signalling a sell bias.
Macro conditions provided little offset. U.S. markets were mixed, with the S&P 500 marginally lower and the Nasdaq down about 0.5%, offering no clear uplift for growth-sensitive European stocks. In Paris, the CAC 40 - Teleperformance’s primary benchmark index - has endured intermittent selling pressure in recent sessions amid global technology-sector concerns, removing a potential cushion for the company’s shares.
The combination of a fresh institutional downgrade using a pessimistic valuation framework, heightened sector narrative around AI substitution risk, and the company’s upcoming half-year results on July 30 has created a cautious investor stance. With the share price hovering nearer the bottom of its 52-week range of €43.65–€90.68, market sentiment appears fragile and management faces the immediate task of demonstrating stabilization at the next reporting date.
Key context:
- Shares fell 5.9% to €51.96 after JPMorgan reinstated coverage with an Underweight rating and EUR 44 price target.
- JPMorgan’s models are about 2% below consensus on operating EBITA and about 12% below on free cash flow, with a DCF outlook that assumes no terminal growth.
- Industry and company-level signals - including Concentrix’s guidance cut and Teleperformance’s Q1 2026 revenue decline of 2.2% on a like-for-like basis - have intensified investor caution.